A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease

Masaki Hanibuchi(Tokushima University), Yasuhiko Nishioka(Tokushima University), Kenji Otsuka(Tokushima University), Hiroshi Nokihara(Tokushima University Hospital), Yuko Toyoda(Tokushima University), Masahiko Azuma(Tokushima University), Hisatsugu Goto(Tokushima University), Eiji Shimizu(Chiba University), Takashi Haku(Tokushima Prefectural Central Hospital), Shinji Atagi(National Institute of Technology, Nara College), Hiroshi Kawano(Shizuoka Cancer Center), Soji Kakiuchi(Tokushima Prefectural Central Hospital), Satoshi Sakaguchi(Tokushima University Hospital), Mayo Kondo(Kobe Medical Center), Fumitaka Ogushi(Tokushima University)
Lung Cancer
September 12, 2018
10.1016/j.lungcan.2018.09.007
Cited by 31

Related Papers

Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations
|Cancer Research|2008|642
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
|The Lancet Oncology|2015|412
Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs
|Oncogene|2003|324
Effects of Surgery With Salvage Stereotactic Radiosurgery Versus Surgery With Whole-Brain Radiation Therapy in Patients With One to Four Brain Metastases (JCOG0504): A Phase III, Noninferiority, Randomized Controlled Trial
|Journal of Clinical Oncology|2018|186